RedHill antibiotic drug Talicia approved by FDA to treat adult H. coli infection

RedHill's share stake on the Tel Aviv Stock Exchange rose more than 13 percent after Talicia's approvalIn addition, the company received a $59 million strategic investment from Cosmo PharmaceuticalsTalicia is the first FDA-approved three-in-one oral capsule based on the antibiotic rifabutinRedHill released the results of Talicia's Phase III validation trial in December 2018, which showed that the drug had an 84% eradication rate of Helicobacter pylori and that the bacteria did not show resistanceThe results are a boon for patients with stomach cancerit is understood that more than 50 per cent of the world's population has been infected with Helicobacter pyloriThis bacteria, which is transmitted through the feces, often lives in gastric mucus or gastric mucosa cells with lower stomach acid, and is prone to gastritis and even stomach cancer25 to 40 per cent of infected patients are unable to eradicate gastrointestinal diseases due to the abuse of antibioticsNow, RedHill's biopharmaceutical Talicia is expected to offer new treatment optionsfounded in 2009,RedHill is a biopharmaceutical company that is a leader in the market for patented drugsThe company has an experienced management team headquartered in Tel Aviv, Israel, and has a business operations headquarters in North Carolina, USAIn addition to Talicia, RedHill will continue to develop new gastric disease treatment drugs to meet patients' medical needsin recent years,, the resistance of bacteria to antibiotics has become a long-standing problem that can not be ignoredIn a clinical study based on a sample of 656 male veterans, Helicobacter pylori's resistance to Biaxin increased significantly over five years, according to a 2015 study published in Clinical Gastroenterology and Hepatologybecause of the relatively low price of antibiotics and the high demand for preservation conditions, many biopharmaceutical companies on the market lack the incentive to develop and create new antibiotics face both scientific and economic challenges With up to 2 million H coli infections needed to be treated in the United States each year, RedHill will continue to develop innovative drugs for these diseases and expand its market for products Note: The original text has a limitation